Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: A CYP2D6 multiple-genotype-based modeling analysis and validation

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Yu, Ke Da ^a   Huang, A Ji ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYTOCHROME P450 2D6; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROBABILITY; SENSITIVITY ANALYSIS; WILD TYPE; ALGORITHM; BREAST TUMOR; CLINICAL TRIAL (TOPIC); ENDOCRINE SYSTEM; GENETICS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; ENDOCRINE SYSTEM; FEMALE; GENOTYPE; HUMANS; MARKOV CHAINS; PHARMACOGENETICS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS;

EID: 78650860697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015649     Document Type: Article

References (33)

1. Early-Breast-Cancer-Trialists'-Collaborative-Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
2. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764.
3. Jin Y, Desta Z, Stearns V, Ward B, Ho H, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97: 30-39.
4. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5: 6-13.
5. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacoge-netic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526.
6. Hoskins JM, Carey LA, McLeod HL (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9: 576-586.
7. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, et al. (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45-53.
8. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486-492.
9. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, et al. (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619-629.
10. Lin NU, Winer EP (2008) Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26: 798-805.
11. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, et al. (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27: 3235-3258.
12. Seruga B, Tannock IF (2009) Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol 27: 840-842.
13. Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD (2008) Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol 26: 5227-5232.
14. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, et al. (2007) Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 106: 229-238.
15. Skedgel C, Rayson D, Dewar R, Younis T (2007) Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 101: 325-333.
16. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3: 229-243.
17. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312-9318.
18. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101: 113-121.
19. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, et al. (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19: 56-61.
20. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, et al. (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25: 5187-5193.
21. Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, et al. (2009) The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat in press.
22. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, et al. (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91: 249-258.
23. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, et al. (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7: R284-290.
24. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, et al. (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9: R7.
25. Punglia RS, Burstein HJ, Winer EP, Weeks JC (2008) Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 100: 642-648.
26. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302: 1429-1436.
27. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, et al. (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83: 234-242.
28. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, et al. (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25: 3837-3845.
29. Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, et al. (2006) Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24: 3708-3709; author reply 3709.
30. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, et al. (2008) A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 14: 811-816.
31. Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, et al. (2008) Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 14: 5864-5868.
32. Desta Z, Flockhart DA (2007) Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol 25: 5147-5149.
33. Hemeryck A, Belpaire FM (2002) Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 3: 13-37.